Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nicol

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual CancerLuca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.
BJU International|December 11, 2024
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumourLuca Antonelli, Axel Heidenreich, Aditya Bagrodia, et al.
World Journal of Urology|March 13, 2022
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibilityChristian D Fankhauser, Luca Afferi, Sean P Stroup, et al.
Immunity|April 16, 2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established TumorsFrederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, et al.
Cancer Discovery|January 8, 2025
Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.
Cancer Discovery|January 9, 2025
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
Nature Ecology & Evolution|December 24, 2021
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal studyXiao Fu, Yue Zhao, Jose I Lopez, et al.
Genome Biology|August 28, 2014
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionRosalie Fisher, Stuart Horswell, Andrew Rowan, et al.
Cell|April 17, 2018
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx RenalThomas J Mitchell, Samra Turajlic, Andrew Rowan, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual CancerLuca Antonelli, Davide Ardizzone, Isamu Tachibana, et al.
BJU International|December 11, 2024
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumourLuca Antonelli, Axel Heidenreich, Aditya Bagrodia, et al.
World Journal of Urology|March 13, 2022
Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibilityChristian D Fankhauser, Luca Afferi, Sean P Stroup, et al.
Immunity|April 16, 2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established TumorsFrederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, et al.
Cancer Discovery|January 8, 2025
Tracking non-genetic evolution from primary to metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.
Cancer Discovery|January 9, 2025
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx RenalÁngel Fernández-Sanromán, Annika Fendler, Benjy J Y Tan, et al.
Nature Ecology & Evolution|December 24, 2021
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal studyXiao Fu, Yue Zhao, Jose I Lopez, et al.
Genome Biology|August 28, 2014
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionRosalie Fisher, Stuart Horswell, Andrew Rowan, et al.
Cell|April 17, 2018
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx RenalThomas J Mitchell, Samra Turajlic, Andrew Rowan, et al.
Pageof 9